投资机构Leerink Partners宣布,将生物制药公司Gossamer Bio Inc.的股票评级从“跑赢大盘”下调至“与大盘持平”。与此同时,该机构将其目标股价从6美元大幅调降至1美元,显示出对该公司近期前景的谨慎态度。
投资机构Leerink Partners宣布,将生物制药公司Gossamer Bio Inc.的股票评级从“跑赢大盘”下调至“与大盘持平”。与此同时,该机构将其目标股价从6美元大幅调降至1美元,显示出对该公司近期前景的谨慎态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.